Lexicon Pharmaceuticals, Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +12.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.06 | $-0.06 | +0.0% | Beat | Q2 FY26 call |
| Q1 FY26 | $-0.04 | $0.00 | +100.0% | Beat | |
| Q4 FY25 | $-0.07 | $-0.04 | +42.9% | Beat | |
| Q3 FY25 | $-0.07 | $-0.04 | +42.9% | Beat | |
| Q2 FY25 | not reported | $0.01 | not reported | not reported | |
| Q1 FY25 | $-0.10 | $-0.07 | +30.0% | Beat | |
| Q4 FY24 | $-0.11 | $-0.09 | +18.2% | Beat | |
| Q3 FY24 | $-0.17 | $-0.18 | -5.9% | Miss | |
| Q2 FY24 | $-0.18 | $-0.17 | +5.6% | Beat | |
| Q1 FY24 | $-0.18 | $-0.20 | -11.1% | Miss | |
| Q4 FY23 | $-0.23 | $-0.20 | +13.0% | Beat | |
| Q3 FY23 | $-0.22 | $-0.21 | +4.5% | Beat |
Back to LXRX overview · LXRX holders · LXRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.